Go or no go? UCB bids to make a mark in psoriasis

UCB’s number-one growth driver, Bimzelx, will get its US regulatory decision this month in psoriasis, but even if it gets the nod it will be a late entrant. Meanwhile, Avadel’s narcolepsy project FT218 will have to contend with a legal challenge from Jazz if it gets a green light.

Also, Chemocentryx will find out whether its filing amendment for avacopan is enough for approval, and Jaks from Pfizer, Lilly and Abbvie might finally get closure after numerous regulatory delays caused by a safety review of the class.